
An experimental medication for critically ill COVID-19 patients appears to work so well that the drug’s maker announced Monday it has stopped its clinical trial early and will apply for emergency use authorization. The medication, sabizabulin, halved the death rate in COVID-19 patients who were receiving supplemental oxygen and were at high risk of serious… read on > read on >